1. Introduction {#s1}
===============

Peripheral neuropathic pain may follow as a direct consequence of a lesion or disease affecting the peripheral somatosensory system.^[@R57]^ Clinically, patients with neuropathies are characterized by negative signs and symptoms (hypoesthesia and hypoalgesia), whereas those with neuropathic pain additionally suffer from positive signs and symptoms (spontaneous and evoked pain).^[@R34]^ Although several hypotheses have been proposed to explain the complex processes of pain and its underlying mechanisms, the pathophysiology of neuropathic pain remains unclear.^[@R3],[@R4],[@R61]^ In this sense, the fact that some patients with nerve damage develop neuropathic pain but others do not represents a substantial issue to be addressed.

Several studies indicate that neuropathic pain is associated with damage to the nociceptive pathways.^[@R4],[@R15],[@R17],[@R60]^ However, many patients with such lesions do not develop neuropathic pain.^[@R6]^ Indeed, clinical examination and other routine diagnostic tools assessing function and structure of somatosensory pathways as well as skin biopsies were unable to reveal differences between patients with and without neuropathic pain after nerve injury.^[@R28],[@R32],[@R58],[@R62]^ The same applies to studies investigating the nociceptive pathways; it was demonstrated that quantitative sensory tests of small-fiber function did not distinguish between patients with and without peripheral neuropathic pain.^[@R28],[@R59]^

By contrast, patients with central pain after spinal cord injury had preserved capsaicin-sensitive pathways as compared to individuals who had suffered spinal cord injury but did not experience pain.^[@R64]^ This finding is in line with evidence from basic research indicating that capsaicin-sensitive neurons play a crucial role in transmitting pain and may be involved in chronic pain.^[@R39],[@R47],[@R50],[@R64]^

Physiologically, both heat- and capsaicin-induced pain are mediated by the majority of nociceptive C fibers through TRPV1, a heat-sensitive ion channel of the transient receptor potential family.^[@R3],[@R11],[@R30]^ Moreover, the activation of these pathways may induce an axon reflex flare, which is caused by the release of vasoactive substances from axon collaterals of afferent nociceptive C fibers, eg, calcitonin gene-related peptide (CGRP).^[@R7],[@R22],[@R24],[@R26]^ The size of the axon reflex erythema reflects a morphological parameter that depends on the individual C-fiber topography and its degree of overlap.^[@R10]^ On the contrary, the blood perfusion is a more functional parameter and reflects a CGRP liberation by detecting even subtle changes in microcirculation. However, the microcirculatory blood perfusion also depends on the border of the axon reflex flare area. Thereby, single-point probe blood perfusion measurements also dependent on morphology.

A classification of different C-fiber subtypes was conducted using microneurographic studies.^[@R37],[@R48]^ Thereby, the CM fibers (= mechanically sensitive C fibers) and the CMi fibers (= mechanically insensitive C fibers) were characterized.^[@R45],[@R46],[@R53],[@R67]^ Most CM fibers are sensitive to both heat and capsaicin stimuli (ie, polymodal C fibers; CMH), whereas only a subpopulation of the CMi fibers is susceptible to both stimuli.^[@R38],[@R46]^ Further on, it was demonstrated that the capsaicin-induced axon reflex erythema is only mediated through the CMi fibers,^[@R45],[@R46]^ whereas the CMH fibers do not affect the axon reflex.

In this study, it was hypothesized that hyperactive C-fiber function contributes to pain. Therefore, the primary objective was to investigate the function of capsaicin-sensitive afferents in both patient groups, with and without peripheral neuropathic pain and healthy volunteers.

2. Methods {#s2}
==========

2.1. Study population {#s2-1}
---------------------

In total, 18 patients with polyneuropathies and (A) 9 healthy age- and sex-matched controls were investigated. The patient cohort included 2 subgroups ie, (B) 9 patients with spontaneous neuropathic pain and (C) 9 pain-free patients. All patients, with and without neuropathic pain, suffered from bilateral polyneuropathies with signs of warmth hypoesthesia (ie, warm detection threshold: z-profile \[0\] to \[−2.5\]), indicating loss of afferent function (verified by quantitative sensory testing \[QST\], see 2.3). All patients were selected according to their warm detection threshold as other studies identified WDT as a highly reliable parameter for C-fiber function.^[@R1],[@R44]^ All patients suffered from polyneuropathies affecting the extremities bilaterally. Diagnosis of polyneuropathy was based on consensus criteria for a symmetric polyneuropathy^[@R18]^ (ordinal likelihood ++++). Subjects younger than 18 years, pregnant women, and subjects with evidence of allergy to capsaicin were excluded.

The aim of the study and the nature of the tests were explained to the subjects in accordance with the Declaration of Helsinki. The study was approved by the ethics committee of the University Hospital of Kiel, and all patients provided written informed consent.

2.2. Study protocol {#s2-2}
-------------------

According to the subgroup (A, B, and C), the testing was performed at the dorsomedial foot within the area of pain in neuropathic pain patients (B); within the area that was clinically affected by polyneuropathy in pain-free patients (C); and within the corresponding area (ie, dorsomedial foot) in control subjects (A).

The first part consisted of a baseline QST within the respective test area. Thereafter, a gauze pad was soaked with 0.3 ml capsaicin (0.6%) and applied to the test area for a duration of 15 minutes. Within this period, blood perfusion was continuously monitored by laser Doppler flowmetry. In addition, subjects were instructed to rate the change in pain perception (ie, capsaicin-induced pain) every minute on an 11-point numeric rating scale (NRS 0--10).

The second part involved the measurement of the visible capsaicin-evoked axon reflex flare area (another 15 minutes after removing the gauze pad). Thereafter, a follow-up QST was performed within the test area.

Local temperature at the test area was kept constant by a feedback-controlled heating device set at 32°C. In this way, the temperature-dependent capsaicin effects could be minimized.^[@R7],[@R63],[@R65]^ All experiments were performed in a room with a constant temperature of 22 to 23°C and a relative humidity of 50% to 60%.

2.3. Quantitative sensory testing {#s2-3}
---------------------------------

Quantitative sensory testing was performed according to the standards of the German Research Network on Neuropathic Pain.^[@R33],[@R41],[@R42]^ A shortened version of 4 different thermal tests was used for standardized assessment of small-fiber function. Thermal QST was performed with a thermo-test device (TSA 2001-II; Medoc, Ramat Yishai, Israel) to investigate perception thresholds for warmth (= warm detection threshold, \[WDT\]), cold (= cold detection threshold, \[CDT\]), heat pain (= heat pain threshold, \[HPT\]), and cold pain (= cold pain threshold, \[CPT\]).^[@R19],[@R68]^ Thereby, the method of limits was used by applying ramp stimuli at a velocity of 1°C/second starting from 32°C applied to the skin using a Peltier type thermode (3 × 3 cm^2^).

The subjects were instructed to press a button when the respective thermal sensation was perceived. Cutoff temperatures were 0 and 50°C, respectively.

2.4. Capsaicin challenge {#s2-4}
------------------------

A 0.3 ml aliquot of a solution containing 0.02 M capsaicin (0.6%), dissolved in 45% ethanol (Kieler Hofapotheke, Kiel, Germany), was applied to the skin using a 3 × 3 cm^2^ large gauze pad for 15 minutes.^[@R3],[@R7],[@R11],[@R30],[@R64]^ To prevent the ethanol from evaporating, the gauze pad was covered with adhesive film.

2.5. Laser Doppler flowmetry {#s2-5}
----------------------------

A perfusion measurement system (Periflux System 5000; Perimed, Stockholm, Sweden) was used to measure perfusion with the laser Doppler probe (Probe 413; Perimed) directly applied to the skin. Perfusion needed to be determined in an area (ie, primary area) surrounding the gauze pad as this prevented measurements within the stimulation area (ie, application area).

2.6. Axon reflex flare reaction {#s2-6}
-------------------------------

Topical capsaicin induces an axon reflex flare reaction by releasing vasodilating neuropeptides (eg, CGRP) from the axon collaterals of vasoactive capsaicin-sensitive nociceptive afferents.^[@R7],[@R45],[@R63]--[@R65]^ Fifteen minutes after removing capsaicin, the visible area of capsaicin-evoked flare was drawn on sheets of plastic film and the area was measured using an irregular area calculator software (SketchAndCalc, 2017).

2.7. Statistical analysis and z-transformation {#s2-7}
----------------------------------------------

Each QST parameter was z-transformed according to a calculation paradigm invented by Magerl et al.^[@R33],[@R42]^ To generate location-, gender-, and age- matched data, this analysis was based on 180 healthy controls. Z-scores of 0 represent the exact mean value of the healthy cohort, whereas z-scores above 0 represent a gain of function and scores below 0 represent a loss of function. Demographic data were displayed as mean (±SEM). Z- transformed data, blood perfusion measurement (area under the curve \[AUC\]), and axon reflex flare size data were displayed as boxplot (minimum, first quartile, median, third quartile, and maximum). Further on, the time course of blood perfusion change and the change of pain ratings were displayed as mean (±SEM). The Mann--Whitney *U* test was applied for unpaired data analyses and the Wilcoxon signed--rank test for paired data analyses (SPSS 23.0; SPSS, Inc, Chicago, IL). All correlation analyses were conducted using Spearman correlation.

*P* values \<0.05 were considered as statistically significant. The Bonferroni--Holm correction was applied.

3. Results {#s3}
==========

3.1. Characterization of patients {#s3-1}
---------------------------------

In total, 18 patients with peripheral neuropathies and 9 healthy volunteers were investigated. The patient group consisted of 2 subgroups, including (B) 9 patients with neuropathic pain (4 women, mean age 65 \[±3.2\] years) and (C) 9 pain-free patients (3 women, mean age 63 \[±3.1\] years) (Table [1](#T1){ref-type="table"}). (A) The healthy volunteers group (4 women, mean age 56 \[±3.4\] years) consisted of 9 subjects without any history or clinical signs of neurological disorders.

###### 

Characterization of patient groups and healthy cohort.
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3.2. Quantitative sensory testing and capsaicin challenge {#s3-2}
---------------------------------------------------------

Before capsaicin challenge, baseline QST revealed a significantly increased WDT (ie, reduced z-values in WDT) in both patient groups as compared to healthy volunteers (A vs B *P* = 0.004; A vs C *P* = 0.004; the Mann--Whitney *U* test) but no difference between patient groups (*P* = 0.863; the Mann--Whitney *U* test). Signs of heat hypoalgesia (ie, increased HPT) were only demonstrated in the patients with pain as compared to controls (*P* = 0.002; the Mann--Whitney *U* test) (Fig. [1](#F1){ref-type="fig"}). After treating small-fiber afferents with topical capsaicin, a follow-up QST was conducted, without indicating any significant differences in QST parameters between groups.

![QST profiles. Indicated are QST profiles of the painful (1), painless (2) and healthy control group (3), before and after capsaicin (CAP) application. Each QST parameter is displayed as boxplot (minimum, maximum, median, and first and third quartiles). Intraindividual statistical testing (ie, before vs after capsaicin application) was conducted using the Wilcoxon signed--rank test. Interindividual statistical testing (ie, between patient groups and healthy cohort) was conducted using the Mann--Whitney *U* test. \*\*\*\<0.001, \*\*\<0.01, n.s. \>0.05. CPT, cold pain threshold; HPT, heat pain threshold; QST, quantitative sensory testing.](painreports-4-e709-g002){#F1}

Further on, a comparison of baseline and follow-up QST parameters was conducted. Results revealed an increase of z-values in WDT and HPT in both patient groups as well as in the control group (WDT and HPT for all 3 groups prior vs after capsaicin: *P* \< 0.01; the Wilcoxon signed-rank test) (Fig. [1](#F1){ref-type="fig"}).

The maximum pain ratings after capsaicin application (ie, at minute 15) (A vs B *P* = 0.190; A vs C *P* = 0.063; B vs C *P* = 0.489; the Mann--Whitney *U* test) as well as the continuous pain rating during capsaicin application (ie, AUC from minute 0--15) (A vs B *P* = 0.222; A vs C *P* = 0.063; B vs C *P* = 0.340; the Mann--Whitney *U* test) did not reach any significant differences between groups (Fig. [2](#F2){ref-type="fig"}).

![Capsaicin challenge and vasoactive reaction. (A) Setup of the experimental capsaicin application procedure. In the application area, the capsaicin patch was applied and the sensory testing was conducted. In the primary area, the continuous blood perfusion measurement as well as the margin of the axon reflex erythema was determined. (B) The axon reflex flare area (cm^2^) after 15 minutes of topical capsaicin application is displayed as boxplot (minimum, maximum, median, and first and third quartiles). There were no significant differences between the patient groups and healthy subjects. Capsaicin induced a larger axon reflex flare in the neuropathic pain patients than in the patients without pain. The application area (9 cm^2^) was not included in the total axon reflex flare size. Interindividual statistical testing for axon reflex flare area was conducted using the Mann--Whitney *U* test. \*\*\<0.01. (C) Displayed is the time course of mean (±SEM) blood perfusion change (arbitrary perfusion units, % change \[PU%\]) in the primary area and the mean (±SEM) pain rating change (numeric rating scale 0--10) during capsaicin challenge. Interindividual statistical testing for maximum pain ratings (ie, at minute 15) was conducted using the Mann--Whitney *U* test (statistically not significant). (D) The area under the curve for blood perfusion (AUC \[PU%\]) is displayed as boxplot. Indicated is a significant difference between the patients with pain as compared to the painless and normal subgroups. Interindividual statistical testing for mean blood perfusion (AUC) between subgroups was conducted using the Mann--Whitney *U* test. \*\<0.05.](painreports-4-e709-g003){#F2}

3.3. Capsaicin-evoked axon reflex flare and blood perfusion {#s3-3}
-----------------------------------------------------------

Results from laser Doppler flowmetry indicate an increased response after capsaicin challenge in painful neuropathy patients as compared to healthy volunteers (*P* = 0.019; the Mann--Whitney *U* test) and painless neuropathy patients (*P* = 0.021; the Mann--Whitney *U* test) (Fig. [2](#F2){ref-type="fig"}).

By contrast, no differences were found in the size of capsaicin-induced flare between healthy controls and patient groups (painful polyneuropathy \[PNP\] vs healthy controls *P* = 0.17; painless PNP vs healthy controls *P* = 0.09; the Mann--Whitney *U* test). However, the axon reflex flare size seemed to change towards an increase in neuropathic pain patients as compared to patients without pain (*P* = 0.002; the Mann--Whitney *U* test) (Fig. [2](#F2){ref-type="fig"}).

Further on, a correlation analysis revealed a significant correlation of the HPT delta (ie, \[baseline HPT\] − \[follow-up HPT\]) and flare in neuropathic pain patients (*P* = 0.004, rho = 0.912; the Spearman correlation). There was no correlation between the axon reflex flare size and the maximum pain rating after capsaicin application (ie, at minute 15) (*P* = 0.565, rho = 0.130; Spearman correlation) or the continuous pain rating during capsaicin application (ie, AUC from minute 0--15) (*P* = 0.472, rho = 0.162; Spearman correlation).

4. Discussion {#s4}
=============

In this study, thermosensitive small-fiber function was assessed by quantitative thermal testing before and after a capsaicin challenge in patients with and without peripheral neuropathic pain. All patients suffered from peripheral neuropathy, with reduced warm detection indicating loss of small-fiber function due to neuropathy.

The major findings in this study were that (1) no significant differences in HPT could be detected between the 2 patient groups before applying capsaicin; (2) after topically applying capsaicin, a significant reduction in HPTs (ie, heat hyperalgesia) was found in both patient groups without any significant differences between the groups; and (3) the extent of capsaicin-induced blood perfusion was greater in patients with pain than in painless patients and in healthy volunteers.

4.1. Determinants for WDT and heat pain threshold {#s4-1}
-------------------------------------------------

Our results are in line with previous studies, indicating no differences when comparing neuropathy patients with and without pain on thermal quantitative testing.^[@R28],[@R31],[@R59]^ However, these findings reflect the function of the whole thermoafferent system, implying that both centrally and peripherally located pain processing mechanisms determine QST results. To which proportion the different components of the pain pathway are modulated by chronic pain remains unclear yet. Indeed, these circumstances might contribute to the fact that no differences between patient groups could be detected on QST. Even if an isolated peripheral C-fiber dysfunction was present in 1 patient group, this sensation could be modified due to central adaption processes and thereby not detectable by psychophysical testing.

4.2. Mismatch of damage to small-fiber afferents---key to understanding neuropathic pain? {#s4-2}
-----------------------------------------------------------------------------------------

In this study, capsaicin induced an axon reflex erythema in both patient groups and in the control group, which indicates the presence and integrity of CMi fibers in neuropathy patients with and without pain. Interestingly, there was a difference in the extent of the capsaicin-induced vasoactive response. The size of capsaicin-induced flare and the blood perfusion in neuropathic pain patients were significantly increased as compared to patients not experiencing pain. However, results from the axon reflex erythema indicate that the flare size of healthy controls is within the range of both patient groups (Fig. [2](#F2){ref-type="fig"}). By contrast, the laser Doppler indicated a different blood perfusion change between the painful PNP patients as compared to the painless PNP group and healthy controls. This suggests that the laser Doppler might be more sensitive in detecting even subtle changes in microcirculation than estimating the flare size with the eye. However, the axon reflex flare has a sharp border; thus, the microcirculatory blood perfusion also depends on the border of the axon reflex flare area. Vice versa, the axon reflex flare size depends on the total dose of CGRP release, which increases with more C-fiber overlap or hyperexcitability. This needs to be considered when interpreting results from a single-point probe perfusion measurement.

Still, in line with these results, a microneurographic study found a different distribution between C-fiber subgroups. Interestingly, the ratio between CM fibers and CMi fibers in healthy volunteers was 2:1. In neuropathy patients with pain, the relationship was reversed between CM fibers and CMi fibers.^[@R40]^ In previous studies, mechanical hyperalgesia as well as central sensitization have been linked to CMi fibers.^[@R27],[@R46],[@R47],[@R50]^ Moreover, a recent microneurography study indicated that a stimulation of CMi fibers induced secondary mechanical hyperalgesia.^[@R43]^ This supports the notion that CMi fibers might act as key players in neuropathic pain. Indeed, our results support either a change of C-fiber ratio, ie, (1) due to a reduction of CMH fibers but preserved number of CMi fibers or (2) due to a disease-related increase or hyperexcitability of CMi fibers.

By contrast, other studies have shown results different from those of ours. For example, Kramer et al.^[@R29]^ found that the size of the axon reflex flare after an electrically evoked axon reflex in patients with diabetic small-fiber neuropathy was smaller than that in healthy subjects. However, they did not differentiate whether the patients suffered from neuropathic pain or had a neuropathy without pain. Moreover, the electric stimuli applied in the latter study activated all axons directly so that the axon reflex flare reflects the activation of all vasoactive nerve fibers (eg, mechanically insensitive C-fiber-histamine positive, CMiHis) and not only the CMi fibers. Another study examined the histamine-induced flare in patients with small-fiber neuropathy and neuropathic pain in comparison to healthy subjects.^[@R8]^ In this study, the axon reflex flare in neuropathic pain patients was decreased. One explanation for the discrepancy of the results of this study might be that a different subgroup of vasoactive C fibers (ie, CMiHis) is histamine sensitive.^[@R47],[@R49]^

Still, the question why capsaicin-induced pain ratings do not develop according to the blood perfusion increase remains (Fig. [2](#F2){ref-type="fig"}). Numeric rating scale pain ratings represent psychometric parameters, and alterations of such parameters may occur easily due to diverse factors (ie, socioeconomic factors, beliefs, etc.).^[@R54],[@R55]^ Therefore, and also due to the small sample size, an exact pathomechanistic explanation for this observation may be too speculative at this point.

4.3. Clinical implications {#s4-3}
--------------------------

Upregulation of TRPV1 channels or increased expression of voltage-gated sodium channels on the C fibers significantly contributes to the development of neuropathic pain.^[@R11]--[@R13],[@R16],[@R23],[@R56],[@R66]^ Therefore, the use of drugs modulating this channel was examined both in animal experiments and in controlled clinical trials.^[@R14],[@R20],[@R21]^ For example, a single application of highly concentrated capsaicin (8%) had an analgesic effect in subgroups of patients with different etiologies of neuropathic pain (ie, postherpetic neuralgia, HIV polyneuropathy, and painful radiculopathy).^[@R2],[@R5],[@R51],[@R52]^ Highly concentrated capsaicin induces reversible degeneration of capsaicin-sensitive nociceptive endings in the epidermis. However, only in a subset of patients treated with high-dosage capsaicin (8%) an analgesic effect could be achieved. A few studies aimed at identifying responders by patient-reported outcome parameters (eg, painDETECT, pain intensity \[NRS\]), intraepidermal anatomical nerve fiber counts, as well as QST.^[@R9],[@R25],[@R36]^ Despite all these approaches, the most robust predictor identified so far was the duration of pain (ie, for less than 6 months), suggesting that these patients might suffer from less central sensitization.^[@R35]^ The fact that sensory testing, morphological nerve fiber structure, as well as questionnaires may not differentiate between functionality of CMH and CMi fibers and that central mechanisms contribute to pain might explain these observations.

However, this implicates that a more specified classification with methods such as a standardized capsaicin challenge or other techniques inducing CMi flare reaction could act as predictive parameters for potential substances targeting TRPV1.

4.4. Conclusions {#s4-4}
----------------

Preserved or hyperexcitable vasoactive (capsaicin-sensitive) C fibers in patients with length-dependent neuropathy and signs of small-fiber dysfunction may contribute to the persistence of certain peripheral pain states. Therefore, the CMi fiber may play a crucial role in a painful condition. By targeting these nociceptors and scrutinizing their functionality, prediction of response could be determined for compounds targeting TRPV1. In the future, further studies need to assess whether a topical capsaicin (8%) treatment in patients with hyperexcitable CMi fibers may be more beneficial.

4.5. Limitations {#s4-5}
----------------

The small sample size in both patient groups and the healthy cohort can be seen as a limitation. Therefore, further studies are needed to confirm our pathophysiological findings.
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